ERBB2 and breast cancer: The study found that, in patients with pretreated ERBB2-positive advanced breast cancer, despite acceptable safety and significant clinical benefits, margetuximab plus chemotherapy exhibited unfavorable cost-effective result over trastuzumab plus chemotherapy.